Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension

This study has been completed.

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00400218

Purpose

Evaluate the safety and anti-hypertensive efficacy of hyzaar(R) in patients with mild to moderate essential hypertension.

Condition	Intervention	Phase
Hypertension	Drug: MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks	Phase III

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Hydrochlorothiazide Losartan Losartan potassium Potassium chloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Official Title:	Evaluate the Safety and Tolerability of Hyzaar(R) (Losartan 50 Mg/ Hydrochlorothiazide 12.5 Mg) In the Treatment of Hypertension

Further study details as provided by Merck:

Primary Outcome Measures:

Blood pressure over 12 weeks
Safety and Tolerability.

Estimated Enrollment:	30
Study Start Date:	September 2005

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient is either receiving high blood pressure monotherapy or no treatment
Patient will have reached the legal age by the time enter the study
Patients diagnosed with mild to moderate essential high blood pressure or high blood pressure with other conditions such as diabetes or cardiovascular diseases and are taking high blood pressure medication (exclude diuretic), but did not meet treatment goal

Exclusion Criteria:

Patient with high levels of uric acid in the blood who has received medications for uric acid in the urine within 3 months prior to enrollment
Patients who are hypersensitive to any component of the study medication
Patients who are hypersensitive to other sulfonamide-derived drugs
Patients with anuria (hyzaar(R) is not recommended for patients with hepatic impairment or severe renal impairment, creatinine clearance </= 30 ml/min)
Unstable diabetes (hba1c > 8%), or a change in diabetes medication during study treatment. patients with stable diabetes may enter the study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00400218

Locations

Taiwan
Merck Sharp & Dohme (I.A.) Corp.
Taipei, Taiwan, 106

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

Study ID Numbers:	2006_049
Study First Received:	November 15, 2006
Last Updated:	February 2, 2007
ClinicalTrials.gov Identifier:	NCT00400218
Health Authority:	Taiwan: National Bureau of Controlled Drugs

Study placed in the following topic categories:

Losartan
Vascular Diseases
Essential hypertension

Angiotensin II
Hydrochlorothiazide
Hypertension

Additional relevant MeSH terms:

Molecular Mechanisms of Pharmacological Action
Diuretics
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

Membrane Transport Modulators
Angiotensin II Type 1 Receptor Blockers
Natriuretic Agents
Therapeutic Uses
Cardiovascular Diseases
Anti-Arrhythmia Agents

ClinicalTrials.gov processed this record on January 16, 2009